Shares of Transcat, Inc. (NASDAQ:TRNS) have been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has assigned a strong buy rating to the company.
Analysts have set a 12 month consensus price target of $28.17 for the company and are anticipating that the company will post $0.26 EPS for the current quarter, according to Zacks. Zacks has also assigned Transcat an industry rank of 106 out of 256 based on the ratings given to related companies.
Several research firms recently issued reports on TRNS. Zacks Investment Research raised shares of Transcat from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 11th. ValuEngine raised shares of Transcat from a “hold” rating to a “buy” rating in a research report on Monday, February 4th.
NASDAQ TRNS traded down $0.20 during mid-day trading on Friday, hitting $24.15. The company’s stock had a trading volume of 114 shares, compared to its average volume of 17,062. Transcat has a twelve month low of $16.50 and a twelve month high of $25.35. The company has a current ratio of 2.16, a quick ratio of 1.45 and a debt-to-equity ratio of 0.40. The company has a market cap of $174.53 million, a P/E ratio of 34.34, a PEG ratio of 2.98 and a beta of 0.90.
Institutional investors and hedge funds have recently bought and sold shares of the business. BlueCrest Capital Management Ltd purchased a new stake in shares of Transcat during the first quarter valued at approximately $237,000. Morgan Stanley purchased a new stake in shares of Transcat during the first quarter valued at approximately $36,000. ExodusPoint Capital Management LP purchased a new stake in shares of Transcat during the first quarter valued at approximately $593,000. Marshall Wace North America L.P. boosted its stake in shares of Transcat by 157.5% during the first quarter. Marshall Wace North America L.P. now owns 1,545 shares of the scientific and technical instruments company’s stock valued at $36,000 after purchasing an additional 945 shares during the period. Finally, Punch & Associates Investment Management Inc. boosted its stake in shares of Transcat by 0.8% during the first quarter. Punch & Associates Investment Management Inc. now owns 340,398 shares of the scientific and technical instruments company’s stock valued at $7,822,000 after purchasing an additional 2,700 shares during the period. 58.67% of the stock is currently owned by hedge funds and other institutional investors.
Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
Featured Story: The benefits and drawbacks of dollar cost averaging
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.